Hemisynthesis and preliminary evaluation of novel endocannabinoid analogues.

[1]  A. Makriyannis,et al.  From cannabis to cannabinergics: new therapeutic opportunities. , 2002, Pharmacology & therapeutics.

[2]  A. Finazzi-Agro’,et al.  Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. , 2002, Journal of medicinal chemistry.

[3]  Pierangelo Geppetti,et al.  An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[4]  F. Bymaster,et al.  Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. , 2002, The Journal of pharmacology and experimental therapeutics.

[5]  P. Reggio.  Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[6]  R. Mechoulam,et al.  Cannabinoids and brain injury: therapeutic implications. , 2002, Trends in molecular medicine.

[7]  J. Ramos,et al.  Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. , 2001, Journal of medicinal chemistry.

[8]  J. Walker,et al.  Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain* , 2001, The Journal of Biological Chemistry.

[9]  K. Waku,et al.  Synthesis and biological activities of novel structural analogues of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. , 2001, Bioorganic & medicinal chemistry letters.

[10]  Z. Vogel,et al.  2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Bisogno,et al.  Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. , 2001, Bioorganic & medicinal chemistry letters.

[12]  W. Campbell,et al.  Structure—Activity Relationships Among N‐Arachidonylethanolamine (Anandamide) Head Group Analogues for the Anandamide Transporter , 2000, Journal of neurochemistry.

[13]  A. Makriyannis,et al.  Structure-activity relationships of anandamide, an endogenous cannabinoid ligand. , 1999, Life sciences.

[14]  R. Razdan,et al.  Unique analogues of anandamide: arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas. , 1999, Journal of medicinal chemistry.

[15]  K. Waku,et al.  Evidence That the Cannabinoid CB1 Receptor Is a 2-Arachidonoylglycerol Receptor , 1999, The Journal of Biological Chemistry.

[16]  A. Makriyannis,et al.  Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups. , 1998, Prostaglandins, leukotrienes, and essential fatty acids.

[17]  Z. Vogel,et al.  Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. , 1997, Journal of medicinal chemistry.

[18]  A. Yamashita,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.

[19]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[20]  R. Lerner,et al.  Chemical characterization of a family of brain lipids that induce sleep. , 1995, Science.

[21]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[22]  Z. Yoshida,et al.  A convenient and efficient unsymmetrical ketone synthesis from acid chlorides and alkyl iodides catalyzed by palladium , 1985 .